Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.19 -1.58%

-$0.19 today

Market cap
$859.56M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.99M

Average 1.49M

CRVS Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Corvus Pharmaceuticals, Inc.NASDAQ: CRVS

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 90M shares rose 19.8% year over year, behind the +22.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 12.9% from the prior quarter. Over 3 fiscal years it compounded at +19.7% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +19.8% toward the trailing-twelve-month pace of +22.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
90M+12.9% QoQ
Last fiscal yearDec 2025
79.74M+30.8% YoY
LTMMar 2026
82.59M+22.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.8%——
1 year+30.8%——
3-year CAGR+19.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
79.74M USD
Year-over-year change
+30.8%
4-year CAGR
+17.5%

Weighted Avg Shares (Diluted) vs competitors

How CRVS compares with its peers on the latest reported figures

  • CRVS's LTM Mar 2026 weighted avg shares (diluted) of 82.59M shares is the 7th highest of the 10 companies compared; the peer median is 94.08M shares.
  • Its year-over-year change of +22.4% is the 3rd highest of 9, against a peer median of +14.0%.
  • Over three fiscal years its annual growth of +19.7% compares with a peer median of +10.6%.
CRVS Competitors Peer median
Weighted Avg Shares (Diluted) for CRVS and competitors
Company Period LTM YoY 3-year CAGR
CMPXCompass Therapeutics, Inc.LTM Mar 2026161.95M +17.8%+14.5%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026160.38M +90.2%+28.0%
CHRSCoherus Oncology, Inc.LTM Mar 2026122.27M +6.0%+15.7%
RCUSArcus Biosciences, Inc.LTM Jun 2026116.35M +19.9%+14.3%
CGENCompugen Ltd.LTM Mar 202694.08M +4.2%+2.7%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+3.9%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.59M +22.4%+19.7%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
ADAGAdagene Inc.LTM Jun 202435.23M —+2.9%
NKTRNektar TherapeuticsLTM Jun 202623.04M +63.6%+10.6%
Peer median (excluding CRVS) 94.08M+14.0%+10.6%

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000105K
Gross Profit0000(105K)
Gross Margin—————
Research & Development29.12M24.47M16.53M19.39M33.72M
Selling, General & Admin9.52M8.1M6.88M8.16M9.25M
Operating Expenses38.63M32.57M23.41M27.55M42.87M
Depreciation & Amortization460K367K151K85K105K
EBITDA(42.77M)(40.94M)(26.88M)(62.21M)(15.18M)
EBITDA Margin—————
Operating Income(38.63M)(32.57M)(23.41M)(27.55M)(42.97M)
Operating Margin—————
Interest Income0654K1.58M1.82M2.51M
Interest Expense15K0000
Other Income / Expenses(4.61M)(8.74M)(3.62M)(34.75M)27.69M
Income Before Tax(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Net Margin—————
EPS (Basic)(1.03)(0.89)(0.56)(1.02)(0.19)
EPS (Diluted)(1.03)(0.89)(0.56)(1.02)(0.53)
Weighted Avg Shares41.85M46.55M48.03M60.99M78.96M
Weighted Avg Shares (Diluted)41.85M46.55M48.03M60.99M79.74M

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.